Freemantle N, Bloor K
Centre for Health Economics, University of York.
BMJ. 1996 Jun 8;312(7044):1469-71. doi: 10.1136/bmj.312.7044.1469.
This is the first of three papers to review international policies to control spending on drugs and improve the efficiency of drug use. Policies can target three main groups: patients, prescribing doctors, and the drugs industry. In this paper we examine policies aimed at patients, particularly restrictions on reimbursement (such as prescription charges). Rigorous experimental and quasi-experimental studies suggest that policies to limit the level of reimbursement of drugs reduce the use of essential as well as non-essential drugs and may do more harm than good.
这是三篇系列论文中的第一篇,旨在回顾控制药品支出及提高用药效率的国际政策。这些政策可针对三个主要群体:患者、开处方的医生以及制药行业。在本文中,我们研究针对患者的政策,尤其是对报销的限制(如处方收费)。严格的实验性和准实验性研究表明,限制药品报销水平的政策会减少基本药物和非基本药物的使用,而且可能弊大于利。